Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
181
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 21 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 15, 1997 | Topotecan | EMA EU | Ovarian Carcinoma | Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent… | centralisedEMEA/H/C/000124 | withdrawn | ema |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 1996 | Topotecan | EMA EU | cancer not stated in this record | Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 25, 1996 | Ibandronic Acid | EMA EU | cancer not stated in this record | Treatment of tumour-induced hypercalcaemia with or without metastases. | centralisedEMEA/H/C/000103 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 14, 1996 | Toremifene | EMA EU | Malignant Breast Neoplasm | First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 27, 1995 | Docetaxel | EMA EU | cancer not stated in this record | Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Enzalutamide | EMA EU | Malignant Prostate Neoplasm | Treatment of prostate cancer. | centralisedEMEA/H/C/006612 | approved |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| centralisedEMEA/H/C/000123 |
| approved |
| ema |
| withdrawn |
| ema |
| Jun 25, 1996 | Ibandronic Acid | EMA EU | cancer not stated in this record | Bondronat is indicated for: prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in… | centralisedEMEA/H/C/000101 | approved | ema |
| Jun 20, 1996 | Doxorubicin | EMA EU | cancer not stated in this record | Caelyx pegylated liposomal is indicated: as monotherapy for patients with metastatic breast cancer, where there is an increased… | centralisedEMEA/H/C/000089 | approved | ema |
| centralisedEMEA/H/C/000091 |
| approved |
| ema |
| centralisedEMEA/H/C/000073 |
| approved |
| ema |
| ema |
| — | Bevacizumab | EMA EU | cancer not stated in this record | Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian… | centralisedEMEA/H/C/005611 | withdrawnsince Jun 21, 2021 | ema |